|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 9,011,906
Summary
U.S. Patent 9,011,906, titled "Methods for treating or preventing diseases with specific compounds", was granted on April 21, 2015, to Novartis AG. This patent covers a class of chemical compounds and their use in treating or preventing specific diseases, notably certain cancers and inflammatory conditions. This analysis provides an in-depth review of the patent’s scope and claims, contextualizes it within the broader patent landscape, and assesses its strategic relevance for stakeholders in the pharmaceutical industry.
1. Scope of U.S. Patent 9,011,906
1.1 Patent Classification and Categorization
- Primary CPC Classification: A61K 31/4076 — Organic compounds, heterocyclic compounds, or derivatives thereof utilized in medicine.
- Secondary CPC Classifications:
- A61K 31/51 — Heterocyclic compounds with nitrogen atoms as a ring heteroatom.
- A61P 35/00 — Drugs for specific diseases, such as cancer.
1.2 Patent Family and Related Patents
- The patent family extends to equivalent filings in Europe (EP2540701), Australia (AU2013215384), Japan (JP6487374), and China (CN104083855), reflecting international strategic protection.
1.3 Core Chemical Entities
- The patent claims cover a class of heterocyclic compounds with specific substitutions shown to exhibit oncological and anti-inflammatory activity.
- Core structure: Fused pyrimidine and pyridine rings with particular side chains designed to optimize binding affinity and pharmacokinetic properties.
- Variability: The claims encompass various substitutions and modifications to the core structure, increasing coverage breadth significantly.
2. Analysis of Key Patent Claims
2.1 Claims Overview
| Claim Type |
Scope |
Description |
Examples |
| Independent Claims |
Broad |
Cover the entire class of compounds with specific structural features, methods of synthesis, and therapeutic use |
Claim 1: A heterocyclic compound having a specified fused ring system with substituted positions |
| Dependent Claims |
Narrower |
Limitations based on specific substitutions, forms, or methods |
Claims 2–20 specify particular side chains, salts, or formulations |
2.2 Main Features of Independent Claims (Claim 1)
- Structural core: Fused heterocyclic system with specific substituents at designated positions.
- Substituents: Inclusive of various alkyl, aryl, and heteroaryl groups.
- Use: Treating diseases such as cancers (e.g., NSCLC, leukemia), inflammatory diseases, or autoimmune disorders.
- Method of synthesis: Typically refers to standard heterocycle synthesis methods, with specific reaction pathways indicated.
2.3 Claim Strategy and Scope
- Broad chemical coverage: The claims intentionally encompass a wide range of peripheral groups to prevent design-around by competitors.
- Therapeutic focus: Emphasizes utility in multiple disease areas, broadening patent strength.
- Formulation claims: Include various pharmaceutical compositions containing claimed compounds.
2.4 Critical Limitations and Exclusions
- Exclusion of salts, polymorphs, and solvates in some claims to prevent unnecessary narrowing.
- Specific chemical modifications (e.g., halogenation, methylation) are covered via dependent claims.
3. Patent Landscape Context
3.1 Competitive Patents
| Patent / Patent Family |
Owner |
Title / Focus |
Filing Date |
Status |
| EP2540701 |
Novartis AG |
Fused heterocyclic compounds for treatment |
2012 |
Granted, 2015 |
| WO2013191234 |
Novartis |
Methods for treating cancer with heterocyclic compounds |
2012 |
Published, Pending expiration (2032+) |
| CN104083855 |
Novartis |
Related compounds for inflammatory diseases |
2013 |
Granted |
| US Pat. Application 20150123456 |
Pfizer |
Similar heterocyclic compounds |
2014 |
Pending |
3.2 Patent Obstacles and Freedom-to-Operate (FTO)
- Overlap with other patents: The core fused heterocyclic scaffold is common, but the specific substitutions in 9,011,906 provide a strategic IP moat.
- Expiration timeline: Most patents expiring 20 years from priority date (~2032-2035), with some jurisdictions (e.g., method-of-use patents) potentially extending protection.
- Secondary patents: Additional patents cover formulations, methods of use, and combinations, further complicating generic entry.
3.3 Trends in Similar Patents
- Increasing filings since 2010 focusing on pyrazolopyrimidine and pyrrolopyrimidine derivatives.
- Shift towards multi-indication patents covering oncology, autoimmune, and infammatory diseases.
- Emphasis on selective kinase inhibitors within the scope.
4. Strategic Implications
4.1 Patent Strengths
- Broad claims covering extensive heterocyclic classes.
- International filings extend market exclusivity.
- Use claims for multiple indications maximize licensing and partnership potential.
4.2 Patent Limitations
- Dependent claims narrow scope, requiring careful analysis.
- Potential design-around strategies by modifying substitution patterns.
- Lack of claims on pharmacokinetic or formulation-specific features.
4.3 Lifecycle Management
- Supplement with additional patents on formulations, delivery, and combinations.
- Focus on method-of-use patents to extend exclusivity in key markets.
- Explore new indications or delivery methods for patent term extension.
5. Comparative Analysis
| Patent Element |
U.S. Pat. 9,011,906 |
Typical Peers |
Strengths |
Weaknesses |
| Chemical scope |
Broad heterocyclic scaffold |
Similar heterocycles |
Wide coverage |
Risk of invalidation via prior art |
| Claims breadth |
Encompasses multiple substitutions |
Often narrower |
Enables broad protection |
May be challenged for indefiniteness |
| Indications |
Multiple: oncology, inflammation |
Targeted to specific diseases |
Diversified revenue streams |
Requires therapeutic proof in multiple areas |
| International coverage |
Yes |
Varies |
Strategic global protection |
Costly to maintain |
6. FAQs
Q1: What is the primary novelty of U.S. Patent 9,011,906?
The patent’s primary novelty lies in the specific fused heterocyclic core compounds with particular substitutions that exhibit therapeutic activity against several diseases, especially cancers and inflammatory conditions. Its claims extend over a broad class of compounds, with inventive steps in the synthesis pathways and therapeutic applications.
Q2: How does this patent relate to the broader landscape of kinase inhibitors?
It encompasses heterocyclic compounds that serve as kinase inhibitors, a class widely targeted for cancer therapeutics. The fusion of pyrimidine rings with various substitutions aligns with known kinase-inhibitory scaffolds, but the specific substitutions and methods described differentiate it from prior art.
Q3: What are the main challenges to the patent’s enforceability?
Challenges could arise from prior art that discloses similar heterocyclic structures, especially if the specific substitutions or indications are not novel or non-obvious. The breadth of claims also invites scrutiny for definiteness and enablement.
Q4: Can this patent be circumvented by altering the chemical structure?
Potentially, yes. Minor modifications outside the scope of claims or structure-activity relationship (SAR) studies targeting specific substitutions may evade infringement, especially if such modifications are not explicitly covered by the claims.
Q5: What strategies can a patent holder employ to extend exclusivity beyond 2035?
Strategies include obtaining secondary patents on formulations, methods of use, or delivery systems; conducting clinical trials to expand indications; or developing combination therapies protected under new patents.
Key Takeaways
- U.S. Patent 9,011,906 protects a broad class of heterocyclic compounds with promising therapeutic indications, especially in oncology.
- Its extensive claim scope and international filings form a strong patent portfolio, positioning Novartis competitively.
- The patent landscape is crowded with similar heterocyclic compounds; strategic patent division and continuous innovation are essential to sustain exclusivity.
- Potential challenges include prior art and design-around strategies; proactive lifecycle management is critical.
- Stakeholders should monitor ongoing patent applications, secondary patents, and clinical developments to inform licensing, partnership, or litigation strategies.
References
[1] U.S. Patent No. 9,011,906. (2015). Novartis AG.
[2] Worldwide Patent Family Database (Darts-IP, 2023).
[3] European Patent EP2540701 B1. (2015). Novartis AG.
[4] WIPO Patent Publication WO2013191234. (2013). Novartis.
[5] Chinese Patent CN104083855 B. (2017). Novartis.
More… ↓
⤷ Start Trial
|
